Status:
UNKNOWN
Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
Lead Sponsor:
Rabin Medical Center
Collaborating Sponsors:
Clinique Pasteur
University of Catania
Conditions:
Aortic Stenosis
Mitral Regurgitation
Eligibility:
All Genders
Brief Summary
an international multicentre registry designed to answer 3 clinical questions: 1. Describing the characteristics and outcomes of current patients undergoing aortic + mitral transcatheter heart valve ...
Detailed Description
Transcatheter aortic valve implantation (TAVI) , has revolutionised the treatment for severe aortic stenosis (AS) over the past decade. The use of TAVI is growing exponentially, and the current trend ...
Eligibility Criteria
Inclusion
- For phase 1:
- TAVI+TMVR/r (either as a single or staged procedure).
- Follow up of at least 30 days post TMVR/r (unless deceased) Available TTE and/or TOE data pre and post TAVI + TMVR/r
- For phase 2:
- Patients undergoing successful isolated TAVI
- Assessment of MR grade prior and post TAVI
Exclusion
- Death within 30 days post TAVI
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT04031274
Start Date
September 1 2019
End Date
December 31 2020
Last Update
July 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center - Hsharon Campus
Petah Tikva, Israel, 49100